{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03048253",
      "OrgStudyIdInfo": {
        "OrgStudyId": "OrienX010-II-10"
      },
      "Organization": {
        "OrgFullName": "OrienGene Biotechnology Ltd.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "A Phase I-c Study of Recombinant GM-CSF Herpes Simplex Virus to TreatⅣ M1c",
      "OfficialTitle": "Recombinant Human GM-CSF Herpes Simplex Virus Injection (OrienX010) Standard Injection in Tumor Treatment Scheme Failed M1c Ⅳ Period Malignant Melanoma Spread to the Liver Open I-c Phase of Clinical Trial"
    },
    "StatusModule": {
      "StatusVerifiedDate": "February 2017",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "March 29, 2016",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "October 10, 2017",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "October 28, 2019",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "February 3, 2017",
      "StudyFirstSubmitQCDate": "February 6, 2017",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "February 9, 2017",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "September 29, 2017",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "October 2, 2017",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "OrienGene Biotechnology Ltd.",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "Recombinant human GM-CSF herpes simplex virus injection (OrienX010) is a genetically engineered from Chinese patients oral separation of wild type 1 herpes simplex virus (HSV) as the carrier insert GM-CSF gene therapy drug.After gene recombination technology successively removing ICP34.5, ICP47 and insert the deactivation ICP6 gene, and at the site of the original ICP34.5 insert guided by IE promoter of hCMV human gm-csf gene.The drug after tumor site local injections of dosing, on the one hand, because of the soluble tumor characteristics of herpes simplex virus, reconstructing it after HSV-1 virus carrier at the injection site specific \"soluble tumor\" kill tumor cells;Viral vector expressed in tumor site, on the other hand, to produce high concentrations of GM-CSF enhance the antitumor immune function, play \"beside the destruction effect\", have inhibition effect on the distant metastases.",
      "DetailedDescription": "Subjects were tested drugs within 8 x 107 pfu/ml tumor injection treatment, the injection quantity according to tumor lesion size, injection amount shall not exceed 10 ml each time, injection frequency for every 2 weeks, 4 times per cycle treatment, treatment 2 cycles. Completed at the end of the second cycle after curative effect evaluation, such as the researchers determine continue to medicine can bring benefit to the subjects, can continue to offer benefits to the subjects' potential drug until disease progression, smaller, not tolerance toxicity or participants to withdraw consent."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Melanoma"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Observational",
      "PatientRegistry": "No",
      "DesignInfo": {
        "DesignObservationalModelList": {
          "DesignObservationalModel": [
            "Cohort"
          ]
        },
        "DesignTimePerspectiveList": {
          "DesignTimePerspective": [
            "Prospective"
          ]
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "30",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "OrienX010",
            "InterventionDescription": "Beijing biological technology co., LTD. Research and development of the source and force of recombinant human GM-CSF herpes simplex virus injection (OrienX010), is a genetically engineered type 1 herpes simplex virus (HSV - 1) as the carrier insert GM-CSF gene therapy drug.Its carrier is made of isolated from patients with oral Chinese wild single blister virus type I (CL1), after gene recombination technology successively removing ICP34.5, ICP47 and insert the deactivation ICP6 gene, and at the site of the original ICP34.5 insert guided by IE promoter of hCMV human GM-CSF gene."
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "change of tumor size",
            "PrimaryOutcomeDescription": "According to RECIST1.1 method to evaluate the change of tumor size.",
            "PrimaryOutcomeTimeFrame": "16 weeks"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nBy histological and/or cytology diagnosis Ⅳ M1c malignant melanoma patients with liver metastasis, the lack of an effective method for the conventional or the failure of conventional therapy or recurrence\nGeneral physical status score (ECOG) 0-2 points\nLifetime is expected to more than 4 months\nAlways anti-tumor treatment (including/radiation therapy, immune therapy, targeted therapy, endocrine therapy, etc.) to end more than 4 weeks (using the nitroso urea class and mitomycin chemotherapy drug withdrawal over 6 weeks), and always treat the adverse reaction of restored or stability\n\nExclusion Criteria:\n\nIn the group treated with other experimental drugs within 4 weeks before, but in the intervening clinical research (except such as epidemiological studies)\nIn group of four weeks before received the treatment of herpes simplex virus, such as acyclovir, ganciclovir, respectively.there is galloway, vidarabine, etc\nIn group of four weeks before too much surgery\nScreening stage HSV - 1 antibody IgG and IgM are negative",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      },
      "StudyPopulation": "Melanoma Standard solution phase failure Ⅳ M1c malignant melanoma spread to the liver",
      "SamplingMethod": "Probability Sample"
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Zinan Xiao, MD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+86-15101193329",
            "CentralContactEMail": "znxiao@Oriengene.com"
          },
          {
            "CentralContactName": "Xiao Shu, PHD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+86-13810106187",
            "CentralContactEMail": "xshu@Oriengene.com"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Beijing cancer hospital",
            "LocationStatus": "Recruiting",
            "LocationCity": "Beijing",
            "LocationState": "Beijing",
            "LocationZip": "100010",
            "LocationCountry": "China",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Chuanliang Cui, PHD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "+86-13691489319",
                  "LocationContactEMail": "cuichuanliang@163.com"
                },
                {
                  "LocationContactName": "Mingfeng Wang, Bachelor",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "+86-15935989834",
                  "LocationContactEMail": "wangmingfeng@163.com"
                }
              ]
            }
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000006561",
            "ConditionMeshTerm": "Herpes Simplex"
          },
          {
            "ConditionMeshId": "D000008545",
            "ConditionMeshTerm": "Melanoma"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000018358",
            "ConditionAncestorTerm": "Neuroendocrine Tumors"
          },
          {
            "ConditionAncestorId": "D000017599",
            "ConditionAncestorTerm": "Neuroectodermal Tumors"
          },
          {
            "ConditionAncestorId": "D000009373",
            "ConditionAncestorTerm": "Neoplasms, Germ Cell and Embryonal"
          },
          {
            "ConditionAncestorId": "D000009370",
            "ConditionAncestorTerm": "Neoplasms by Histologic Type"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          },
          {
            "ConditionAncestorId": "D000009380",
            "ConditionAncestorTerm": "Neoplasms, Nerve Tissue"
          },
          {
            "ConditionAncestorId": "D000018326",
            "ConditionAncestorTerm": "Nevi and Melanomas"
          },
          {
            "ConditionAncestorId": "D000006566",
            "ConditionAncestorTerm": "Herpesviridae Infections"
          },
          {
            "ConditionAncestorId": "D000004266",
            "ConditionAncestorTerm": "DNA Virus Infections"
          },
          {
            "ConditionAncestorId": "D000014777",
            "ConditionAncestorTerm": "Virus Diseases"
          },
          {
            "ConditionAncestorId": "D000007239",
            "ConditionAncestorTerm": "Infections"
          },
          {
            "ConditionAncestorId": "D000017193",
            "ConditionAncestorTerm": "Skin Diseases, Viral"
          },
          {
            "ConditionAncestorId": "D000012874",
            "ConditionAncestorTerm": "Skin Diseases, Infectious"
          },
          {
            "ConditionAncestorId": "D000012871",
            "ConditionAncestorTerm": "Skin Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M10680",
            "ConditionBrowseLeafName": "Melanoma",
            "ConditionBrowseLeafAsFound": "Melanoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M16674",
            "ConditionBrowseLeafName": "Virus Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8791",
            "ConditionBrowseLeafName": "Herpes Simplex",
            "ConditionBrowseLeafAsFound": "Herpes Simplex",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M19648",
            "ConditionBrowseLeafName": "Neuroendocrine Tumors",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M18997",
            "ConditionBrowseLeafName": "Neuroectodermal Tumors",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M19540",
            "ConditionBrowseLeafName": "Neuroectodermal Tumors, Primitive",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11470",
            "ConditionBrowseLeafName": "Neoplasms, Germ Cell and Embryonal",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11467",
            "ConditionBrowseLeafName": "Neoplasms by Histologic Type",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11477",
            "ConditionBrowseLeafName": "Neoplasms, Nerve Tissue",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11598",
            "ConditionBrowseLeafName": "Nevus",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11600",
            "ConditionBrowseLeafName": "Nevus, Pigmented",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M19623",
            "ConditionBrowseLeafName": "Nevi and Melanomas",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9435",
            "ConditionBrowseLeafName": "Infections",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5520",
            "ConditionBrowseLeafName": "Communicable Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8795",
            "ConditionBrowseLeafName": "Herpesviridae Infections",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6594",
            "ConditionBrowseLeafName": "DNA Virus Infections",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14826",
            "ConditionBrowseLeafName": "Skin Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M18653",
            "ConditionBrowseLeafName": "Skin Diseases, Viral",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14829",
            "ConditionBrowseLeafName": "Skin Diseases, Infectious",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T4091",
            "ConditionBrowseLeafName": "Neuroendocrine Tumor",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T4092",
            "ConditionBrowseLeafName": "Neuroepithelioma",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC01",
            "ConditionBrowseBranchName": "Infections"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC17",
            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M10262",
            "InterventionBrowseLeafName": "Liver Extracts",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M257523",
            "InterventionBrowseLeafName": "Molgramostim",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Hemat",
            "InterventionBrowseBranchName": "Hematinics"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "ANeo",
            "InterventionBrowseBranchName": "Antineoplastic Agents"
          }
        ]
      }
    }
  }
}